5/22/16-Since our last entry, the following assets were sold from the Low Price to Book Value portfolio:
CSH, bought on 11/14/14, was redeemed on 4/27/16 for a net gain of 58.94%. CSH had been up 50% or more since purchase and its P/Bk ratio was now 1.0 or above.
TCK, bought on 4/18/14, was redeemed on 5/18/16 for a loss of 55.57%. TCK had been held for two years or more since purchase.
TGI, bought on 2/8/16, was redeemed on 5/16/16 for a net gain of 55.86%. TGI had been up 50% or more since purchase and its P/Bk ratio was now 1.0 or above.
These returns are after commissions but do not include any dividends. The buy/sell dates, amounts, and results have been added to our spreadsheet for Low Price to Book Value closed positions and will be incorporated into the stats of our quarterly performance reports.
In addition, the following asset was added to our Dividend Value portfolio:
Shares of WDC were purchased on 5/10/16 for $36.61 a share plus a commission of $9.
Further, shares of INFY were purchased respectively on 5/18/16, for $18.50 a share plus commission, and 5/19/16, for 18.49 a share plus commission, both for our High Quality portfolio.
My favorites at this point are: WDC* for our Dividend Value portfolio; RAIL* for our Low P/Bk portfolio; RAIL*, TARO*, UTHR*, and WETF* for our Low Trailing P/E portfolio; and EXPD plus INFY* for our High Quality portfolio.
Shares of all of these assets are in our nest egg already or being added to it.
(*a new recommendation)
5/31/16-Since our last entry, the following asset was sold from the Low Price to Book Value portfolio:
AEY, bought on 5/20/14, was redeemed on 5/24/16 for a net loss of 42.95%. It had been held for two years or more since purchase.
The indicated return is after commissions but does not include any dividends. The buy/sell dates, amounts, and results have been added to our spreadsheet for Low Price to Book Value closed positions and will be incorporated into the stats of our quarterly performance reports.
On 4/23/16, I noted in this journal's entry that a new set of criteria would be added to our Low Trailing P/E portfolio: "...I am expanding the criteria for the Low Trailing P/E portfolio to include assets with a P/E up to 25 but with the ratio of P/E to historical 3-year earnings growth = to 0.67 or below. Stocks associated with risky countries or with negative PEG, levered free cash flow, or book value or with dividend payout ratios in excess of 0.6 are to be excluded."
It has since been observed that the stocks in this category have characteristics that lend themselves to more frequent buy/sell rebalancing than applies for our more general Low P/E stocks. Accordingly, I shall be treating them as a separate portfolio: Low Tr. P/E to 3-Yr. Earn. Growth. Assets bought in this category shall be above their 20-day simple moving averages at the time of purchase and sold (after held at least three days) once noted to have fallen below their 20-day simple moving averages.
The first of our assets that this affects is TARO, bought on 5/23/16 at $136.50 and sold today (a little below its 20-day moving average) at $145.15, for a net gain, after commissions, but not counting any dividends, of 5.63%. It will be replaced in this portfolio with the next and best candidate that currently meets all purchase criteria: SWKS*. Shares in SWKS are being added to our Low Tr. P/E to 3-Yr. Earn. Growth portfolio today.
(*a new recommendation)
Disclaimer and Disclosure Statement
Neither I nor Investor's Journal will be responsible for losses by anyone who obtained ideas from this site.
This diary is intended for personal interest and general information only. You are advised to do your own research (as well as to consult highly compensated professionals) before spending money on anything.
I know of no reason anyone should take my financial musings seriously. At best I am a dedicated amateur providing a bit of investment-related insight and entertainment, at worst an amusing diversion.
My wife, Fran, and I may at times own shares of some of the assets mentioned here. But neither of us receive any benefit from reference to them, unless you count the mutual misery when we get it wrong, or the opportunity to gloat when we get it right.